Clinical Trial

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-09; most recent amendment 2025-12-04.
Status change: Recruiting → Active, Not Recruiting 2025-08-05
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06967181
Lead Sponsor CyanVac LLC
Conditions Mumps
Enrollment 60 participants
Start Date 2025-05-14
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-11